Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358738 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL14358741 | 0.86 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL18880072 | 0.85 | ALDH1A1 (0.73) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2706148 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2165479 | 0.80 | PSEN1 (0.53) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL12095779 | 0.80 | PSEN1 (0.53) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2165476 | 0.80 | PSEN1 (0.53) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL11338210 | 0.79 | CA1 (0.53) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL11742987 | 0.78 | KMT2A (0.59) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL178429 | 0.78 | MAPT (0.71) | ALDH1A1MAPTKMT2AMEN1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | NAGOYA CITY UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8445516-B2 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-1228087-B1 | ANTIBODY CATALYSIS OF ENANTIO- AND DIASTEREO-SELECTIVE ALDOL REACTIONS | SCRIPPS RESEARCH INST (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7666658-B1 | Antibody catalysis of enantio- and diastereo-selective aldol reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666658-B1 | Antibody catalysis of enantio- and diastereo-selective aldol reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666658-B1 | Antibody catalysis of enantio- and diastereo-selective aldol reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1708705-B1 | USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS | OTSUKA PHARMA CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-6589766-B1 | Use to catalyze ketone-ketone, ketone-aldehyde, aldehyde-ketone, and aldehyde-aldehyde intermolecular aldol reactions, and in some cases to catalyze their subsequent dehydration to yield aldol condensation products | THE SCRIPPS RESEARCH INSTITUTE | 2003-07-08 | — | — | US | disclosed |
| EP-1228087-A1 | ANTIBODY CATALYSIS OF ENANTIO- AND DIASTEREO-SELECTIVE ALDOL REACTIONS | The Scripps Research Institute (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6326176-B1 | ALDOL CONDENSATIONS AND CATALYTIC ANTIBODIES | THE SCRIPPS RESEARCH INSTITUTE | 2001-12-04 | — | — | US | disclosed |
| US-6309881-B2 | ALDEHYDE AND KETONE REACTANTS ARE CONTACTED WITH ANTIBODY MOLECULES OR MOLECULES CONTAINING ANTIBODY COMBINING SITE PORTIONS THAT CATALYZE AN ALDOL ADDITION REACTION | THE SCRIPPS RESEARCH INSTITUTE | 2001-10-30 | — | — | US | disclosed |
| US-20010018201-A1 | Antibody catalysis of enantio- and diastereo-selective aldol reactions | BARBAS CARLOS F (US) | 2001-08-30 | — | — | US | disclosed |
| WO-2001027145-A1 | ANTIBODY CATALYSIS OF ENANTIO- AND DIASTEREO-SELECTIVE ALDOL REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2001-04-19 | — | — | WO | disclosed |
| US-6210938-B1 | CONTACTING ALDEHYDE AND KETONE REACTANTS WITH CATALYTIC ANTIBODIES PRODUCED BY IMMUNIZING SUBJECT WITH STERILE SOLUTION OF ALDOL TRANSITION STATE IMMUNOCONJUGATE INCLUDING A SULFONE BETA-DIKETONE HAPTEN | THE SCRIPPS RESEARCH INSTITUTE | 2001-04-03 | — | — | US | disclosed |
| EP-1038018-A1 | ALDOL CONDENSATIONS BY CATALYTIC ANTIBODIES | The Scripps Research Institute (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031263-A1 | ALDOL CONDENSATIONS BY CATALYTIC ANTIBODIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187025-A1 | Pharmaceutical composition for promoting angiogenesis | FLT1, FLT4, KDR | ALDH1A1 246/4885MAPT 4708/4885KMT2A 3216/4885 |
| US-20010018201-A1 | Antibody catalysis of enantio- and diastereo-selective aldol reactions | ALDOA, DERA, ADH1C | ALDH1A1 63/4885MAPT 1346/4885KMT2A 3321/4885 |
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | RCOR1, MSI2, RCOR3 | ALDH1A1 2604/4885MAPT 2932/4885KMT2A 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.